Aesica has acquired R5, which develops and manufactures new medicines and clinical trial materials, for an undisclosed sum. Chief Executive, Robert Hardy, said the company is currently considering a number of additional takeover targets overseas as part of its expansion plans including a formulation manufacturer in the US and Europe.
North East Business
Thursday, 1 July 2010
Aesica acquires R5, plans more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment